Strategies for the modulation of phase II metabolism in a series of PKCε inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 24, Issue 15, 2014, Pages 3398-3402

  Clemens, Jeremy J ^a   Coon, Timothy ^a   Busch, Brett B ^a   Asgian, Juliana L ^a   Hudson, Sarah ^a   Termin, Andreas ^a   Flores, Tina B ^a   Tran, Dao ^a   Chiang, Peggy ^a   Sperry, Sam ^a   Gross, Ray ^a   Abt, Jeffrey ^a   Heim, Roger ^a   Lechner, Sandra ^a   Twin, Heather ^a   Studley, John ^a   Brenchley, Guy ^a   Collier, Philip N ^a   Pierard, Francoise ^a   Miller, Andrew ^a   Mak, Chau ^a   Dvornikovs, Vadims ^a   Jimenez, Juan Miguel ^a   Stamos, Dean ^a   more..

^a VERTEX PHARMACEUTICALS   (United States)

Author keywords

Glucuronidation; Metabolism; Phase II; PKC ; Polarity

Indexed keywords

ALCOHOL; GLUCURONOSYLTRANSFERASE; PROTEIN KINASE C EPSILON; PROTEIN KINASE C INHIBITOR; VINYL ACETATE; GLUCURONIDE; PROTEIN KINASE INHIBITOR; PROTEIN SERINE THREONINE KINASE INHIBITOR;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG METABOLISM; DRUG STRUCTURE; DRUG SYNTHESIS; GLUCURONIDATION; NONHUMAN; PLASMA CLEARANCE; RAT; SUPERCRITICAL FLUID CHROMATOGRAPHY; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMICAL STRUCTURE; CHEMISTRY; DOG; DOSE RESPONSE; METABOLISM; SPRAGUE DAWLEY RAT; STRUCTURE ACTIVITY RELATION; ANIMAL CELL; DRUG DEGRADATION; ENANTIOMER; HYDROLYSIS; LIVER MICROSOME; PHYSICAL CHEMISTRY; STANDARD;

RATTUS;

ANIMALS; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; GLUCURONIDES; MOLECULAR STRUCTURE; PROTEIN KINASE C-EPSILON; PROTEIN KINASE INHIBITORS; RATS; RATS, SPRAGUE-DAWLEY; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84904040568     PISSN: 0960894X     EISSN: 14643405     Source Type: Journal    
DOI: 10.1016/j.bmcl.2014.05.082     Document Type: Article

References (20)

1. Murphy, P. J. In Handbook of Drug Metabolism, 2nd ed.; Pearson, P. G., Wienkers, L. C., Eds.; Informa Healthcare: New York, 2009; Vol. 186, Chapter 1.
2. R. Iyer, and D. Zhang D. Zhang, M. Zhu, W.G. Humphreys, Drug Metabolism in Drug Design and Development Vol. 1 2008 Wiley - Interscience Hoboken Chapter 9
3. E.H. Kerns, and L. Di Drug-like Properties: Concepts, Structure Design and Methods 2008 Elsevier Oxford Vol. 1, Chapter 11
4. S. Kaivosaari, M. Finel, and M. Koskinen Xenobiotica 41 2011 652
5. G.E. Kuehl, J.W. Lampe, J.D. Potter, and J. Bigler Drug Metab. Dispos. 1027 2005 33
6. C. Goswami, J. Kuhn, O.A. Dina, G. Fernández-Ballester, J.D. Levine, A. Ferrer-Montiel, and T. Hucho J. Neurochem. 117 2011 995
7. Y. Maeno-Hikichi, S. Chang, K. Matsumura, M. Lai, H. Lin, N. Nakagawa, S. Kuroda, and J. Zhang Nat. Neurosci. 6 2003 468
8. C.W. Hodge, K.K. Mehmert, S.P. Kelley, T. McMahon, A. Haywood, M.F. Olive, D. Wang, A.M. Sanchez-Perez, and R.O. Messing Nat. Neurosci. 2 1999 997
9. Y. Akita J. Biochem 132 2002 847
10. C.A. Parada, D.B. Reichling, and J.D. Levine Pain 113 2005 185
11. A. Gonelli, C. Mischiati, R. Guerrini, R. Voltan, S. Salvadori, and G. Zauli Mini-Rev. Med. Chem. 9 2009 498
12. Y. Nakagawa, K. Irie, R.C. Yanagita, H. Ohigashi, K. Tsuda, K. Kashiwagi, and N. Saito J. Med. Chem. 49 2006 2681
13. E.K. Joseph, and J.D. Levine Pain 150 2010 17
14. A. Krasovskiy, and P. Knochel Angew. Chem., Int. Ed. 43 2004 3333
15. S. Lou, and G.C. Fu Adv. Synth. Catal. 352 2010 2081
16. J.J. Song, Z. Tan, J.T. Reeves, F. Gallou, N.K. Yee, and C.H. Senanayake Org. Lett. 7 2005 2193
17. S.E. Schaus, B.D. Brandes, J.F. Larrow, M. Tokunaga, K.B. Hansen, A.E. Gould, M.E. Furrow, and E.N. Jacobsen J. Am. Chem. Soc. 124 2002 1307
18. R. Lucas, D. Alcantara, and J.C. Morales Carbohydr. Res. 344 2009 1340
19. i values were calculated using a Morrison fit protocol (Genedata, San Francisco, CA). Protocol adapted from: J.-M. Jimenez, D. Boyall, G. Brenchley, P.N. Collier, C.J. Davis, D. Fraysse, S.B. Keily, J. Henderson, A. Miller, F. Pierard, L. Settimo, H.C. Twin, C.M. Bolton, A.P. Curnock, P. Chiu, A.J. Tanner, and S. Young J. Med. Chem. 56 2013 1799
20. K. Rose, Y.-S. Yang, R. Sciotti, and H. Cai Drug Metab. Lett. 3 2009 28